Total Anorectal Reconstruction With The American Medical Systems, Inc. Acticon Neosphincter Prosthesis After Abdominoperineal Resection
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials
| City: |
|
New York |
| State: |
|
New York |
| Zip Code: |
|
10065 |
| Conditions: |
|
Anal Cancer - Colorectal Cancer - Perioperative/Postoperative Complications |
| Purpose: |
|
RATIONALE: An anal sphincter prosthesis may replace the need for a permanent colostomy and
may improve the quality of life of patients who are undergoing surgery for anal or rectal
cancer.
PURPOSE: Clinical trial to study the effectiveness of an anal sphincter prosthesis in
treating patients who have anal or rectal cancer and are undergoing surgery to remove the
anus and rectum.
|
| Study Summary: |
|
OBJECTIVES:
- Determine the risk of complications and feasibility of total anorectal reconstruction
using the Acticon Neosphincter prosthesis after abdominoperineal resection in patients
with anal or rectal cancer.
- Determine continence, bowel function, and quality of life of patients treated with this
surgery.
OUTLINE: Patients undergo abdominoperineal resection (APR) with perineal colostomy and
diverting loop ileostomy. At least 3 months after APR, patients undergo placement of the
Acticon Neosphincter prosthesis. At least 6 weeks after prosthesis placement, the prosthesis
is activated. When the patient demonstrates the ability to operate the prosthesis, the
ileostomy is reversed.
Quality of life is assessed at 6 and 12 months and then annually thereafter.
Patients are followed at 6 and 12 months and then annually thereafter.
|
| Criteria: |
|
Subject Inclusion Criteria:
- Histologically proven cancer of distal rectum or anus
- Not candidates for sphincter preservation
- > or = 18 years of age
- an acceptable risk for surgery and general anesthesia
- sufficient dexterity and mental capacity to operate the device
- willing and able to give valid Informed Consent
Subject Exclusion Criteria:
- Patients with recurrent anorectal cancer
- Patients with metastatic anorectal cancer
- Patients at high risk for local recurrence
- Patients with active pelvic sepsis
- Patients currently enrolled in another study involving an investigational product
|
| NCT ID: |
|
NCT00059891 |
| Primary Contact: |
|
Study Chair W. Douglas Wong, MD Memorial Sloan-Kettering Cancer Center
|
| Backup Contact: |
|
N/A |
| Location Contact: |
|
New York, New York 10065 United States
W. Douglas Wong, MD Phone: 212-639-5117
Site Status: Recruiting |
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
May 22, 2013 |
| Modifications to this listing: |
|
Only selected fields are shown, please use the link
below to view all information about this clinical trial. |
|
Click to view Full Listing
|